Myostatin Levels and the Risk of Myopenia and Rheumatoid Cachexia in Women with Rheumatoid Arthritis

Area of Science:

• Biochemistry
• Rheumatology
• Endocrinology

Background:

• Myostatin, a key regulator of muscle mass, has not been previously studied in relation to myopenia within rheumatoid arthritis (RA).
• Rheumatoid arthritis is often associated with muscle wasting conditions like cachexia and low skeletal muscle mass (LSMM).

Purpose of the Study:

• To investigate serum myostatin as a potential biomarker for cachexia and LSMM in RA patients.
• To determine if elevated serum myostatin levels correlate with these conditions, even after accounting for confounding factors.

Main Methods:

• A cross-sectional study involving 161 female RA patients and 72 female controls.
• Skeletal muscle mass index (SMMI) and rheumatoid cachexia were assessed using dual-energy X-ray absorptiometry.
• Serum myostatin levels were measured via ELISA, with ROC analysis to establish a cut-off value for high levels.

Main Results:

• RA patients exhibited higher proportions of LSMM and elevated serum myostatin compared to controls (p < 0.001).
• A serum myostatin level of ≥17 ng/mL was identified as an efficient cut-off for detecting rheumatoid cachexia and LSMM.
• High myostatin levels (≥17 ng/mL) in RA patients significantly increased the risk of cachexia (OR=2.79) and LSMM (OR=3.04).

Conclusions:

• Elevated serum myostatin levels are associated with an increased risk of developing low skeletal muscle mass and rheumatoid cachexia.
• Serum myostatin shows promise as a biomarker for identifying RA patients at risk of myopenia and cachexia.